EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension

Richard J Nowak iD, Ari Breiner, Vera Bril, Jeffrey A Allen, Shaida Khan, Todd Levine, Daniel H Jacobs, Gregory Sahagian, Zaeem A Siddiqi, Jing Xu, William L Macias, Michael Benatar iD und 1 weitere

Annals of Clinical and Translational Neurology · 2024-01 · 11 (1) · 194-206

DOI: 10.1002/acn3.51946 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 07.12.2023. Verfasst von Richard J Nowak und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Activities of Daily Living, Myasthenia Gravis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the safety, tolerability, and key pharmacodynamic effects of subcutaneous batoclimab, a fully human anti‐neonatal Fc receptor monoclonal antibody, in patients with generalized myasthenia gravis and anti‐acetylcholine receptor antibodies.

Methods

A Phase 2a, proof‐of‐concept, randomized, double‐blind, placebo‐controlled trial is described. Eligible patients were randomized (1:1:1) to receive once‐weekly subcutaneous injections of batoclimab 340 mg, batoclimab 680 mg, or matching placebo for 6 weeks. Subsequently, all patients could enter an open‐label extension study where they received batoclimab 340 mg once every 2 weeks for 6 weeks. Primary endpoints were safety, tolerability, and change from baseline in total immunoglobulin G, immunoglobulin G subclasses, and anti‐acetylcholine receptor antibodies at 6 weeks post‐baseline. Secondary endpoints included changes from baseline to 6 weeks post‐baseline for Myasthenia Gravis Activities of Daily Living, Quantitative Myasthenia Gravis, Myasthenia Gravis Composite, and revised 15‐item Myasthenia Gravis Quality of Life scores.

Results

Seventeen patients were randomized to batoclimab 680 mg ( n = 6), batoclimab 340 mg ( n = 5), or placebo ( n = 6). Batoclimab was associated with significantly greater reductions in total immunoglobulin G and anti‐acetylcholine receptor antibodies from baseline to 6 weeks post‐baseline than placebo. Reductions in immunoglobulin G subclasses were generally consistent with total immunoglobulin G. While clinical measures showed directionally favorable improvements over time, the study was not powered to draw conclusions about therapeutic efficacy. No safety issues were identified.

Interpretation

The safety profile, pharmacodynamics, and preliminary clinical benefits observed in this study support further investigation of subcutaneous batoclimab injections as a potential patient‐administered therapy for seropositive generalized myasthenia gravis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Activities of Daily LivingMyasthenia GravisHumansQuality of LifeReceptors, CholinergicAntibodies, MonoclonalAutoantibodiesImmunoglobulin G

Substanzen

Receptors, CholinergicAntibodies, MonoclonalAutoantibodiesImmunoglobulin G

Autor:innen und Institutionen

  • Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Division of Neurology, Department of Medicine, The Ottawa Hospital and Ottawa Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Neurology, UT Southwestern Medical Center, Dallas, Texas, USA.
  • HonorHealth Neurology dba Phoenix Neurological Associates, Phoenix, Arizona, USA.

ORCID-Profile: Richard J Nowak, Michael Benatar

Förderung

  • NCATS NIH HHS

Zitieren

APA

Nowak, R. J., Breiner, A., Bril, V., Allen, J. A., Khan, S., Levine, T., Jacobs, D. H., Sahagian, G., Siddiqi, Z. A., Xu, J., Macias, W. L., Benatar, M., & ASCEND MG Study Group (2024). Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension. Annals of Clinical and Translational Neurology, 11(1), 194-206. https://doi.org/10.1002/acn3.51946

Vancouver

Nowak RJ, Breiner A, Bril V, Allen JA, Khan S, Levine T, et al. Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension. Annals of Clinical and Translational Neurology. 2024;11(1):194-206. doi:10.1002/acn3.51946

BibTeX
@article{Nowak2024,
  author = {Nowak, Richard J and Breiner, Ari and Bril, Vera and Allen, Jeffrey A and Khan, Shaida and Levine, Todd and Jacobs, Daniel H and Sahagian, Gregory and Siddiqi, Zaeem A and Xu, Jing and Macias, William L and Benatar, Michael and ASCEND MG Study Group, ASCEND MG Study Group},
  title = {Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  volume = {11},
  number = {1},
  pages = {194--206},
  doi = {10.1002/acn3.51946}
}
Kostenlos starten →